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pre-RT IIEFp robustly predict the 1-year risk of impotency 
after high-dose RT for PC in HT-naive, potent men. The steep 
relationship with EQD2_D1% suggests that 
avoiding/minimizing the overlap between PTV and PB (likely 
for most pts if using MRI) could dramatically improve potency 
preservation. 
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Purpose/Objective: Stereotactic ablative body radiotherapy 
(SABR) is an emerging non-invasive treatment modality for 
both small and large inoperable primary renal cell carcinoma 
(RCC)1. A dose/effect relationship of renal dysfunction post-
SBRT is yet to be established. We evaluate renal dysfunction 
post-treatment using nuclear medicine imaging and serum 
biochemistry.  
1 Siva S, Pham D, Gill S, et al: A systematic review of stereotactic radiotherapy ablation for 
primary renal cell carcinoma. BJU Int 110:E737-43, 2012 
Materials and Methods: As part of a prospective ethics board 
approved clinical trial, patients with primary RCC received 
single fraction 26Gy SBRT for tumours < 5cm, or 42Gy/3 
fractions of SBRT for tumours ≥ 5cm (biological equivalent 
dose [BED3Gy] of 251Gy and 238Gy, respectively). Prior to 
treatment, 14 days post treatment, and approximately 90 
days post-therapy, glomerular filtration rate (GFR) was 
measured by 51Cr-EDTA clearance and split renal perfusion 
was recorded by 99mTc-DMSA SPECT/CT. A subset of patients 
also underwent late nuclear medicine imaging at 1 year. The 
change in renal perfusion on SPECT/CT over time was 
evaluated across each 1Gy isodose bin. Toxicity was scored 
using Common Toxicity Criteria for Adverse Events (CTCAE) 
v4.0. 
Results: From July 2012 to August 2013, 21 patients were 
enrolled on trial, with a median follow-up of 12 months. In 9 
patients the referral was precipitated by the likely need for 
post-surgery dialysis. Patient characteristics are found in 
Table 1. No patient sustained grade 3+ toxicities, 5/21 
patients (24%) had grade 2 toxicities (fatigue, flank pain, 
haematuria), and 5/21 (24%) patients were asymptomatic 
from treatment. The mean (+/- SD) GFR at baseline was 52 
+/- 24 mls/min and was 55 +/- 32 mls/min at ~90 days 
(p=0.174). In a subset of 14 patients (7 single fraction and 7 
multi-fraction) undergoing late GFR scanning at a median of 
350 days post SBRT, there was a decrease in mean (+/- SD) 
GFR from baseline to 45 +/-14 mls/min (p=0.034). Local split 
functional assessed by SPECT imaging demonstrated linear 
correlation between functional loss and delivered dose 
(Figure 1). For single- and three-fraction cohorts, this was 
calculated at 3.2% and 2.3% percent loss from baseline per Gy 
delivered, respectively (Pearson r2 range 0.499-0.953, all p-
values < 0.001). When normalising both groups by BED, this 
equates to 2.9% per 10Gy BED3Gy (r2= 0.876, p < 0.001). The 
split differential % loss in function in the treated kidney was -
27% (+/- 34%), and split differential % compensatory gain in 
the unaffected kidney was +14% (+/- 28%). The mean serum 
creatinine was worse at 1-year post SBRT at 162 umol/L 
compared to baseline of 131 umol/L (p=0.02). No patient 
required dialysis. 
 





Conclusions: SBRT for primary inoperable RCC appears highly 
tolerable in the short to medium term, without need for 
dialysis. No renal dysfunction is observed up to 90 days post-
SBRT, however decline in global GFR is noted at 1-year. Renal 
dysfunction in the treated kidney was highly dose dependent 
and predictable using BED3Gy estimates. Ongoing late 
assessment of renal function kinetics is warranted. 
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Purpose/Objective: The objective of the current review is to 
compare 5-year overall survival (OS) rates from retrospective 
and prospective studies of radical cystectomy (RC) and 
trimodality treatment (TMT), i.e. concurrent delivery of 
chemotherapy and radiotherapy after a transurethral 
resection of bladder tumor (TURBT), involving a total of 
10265 and 3131 patients, respectively. 
Materials and Methods: In order to assess the best treatment 
approach for MIBC, a PubMed literature search was 
conducted using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) literature 
selection process. All prospective and retrospective studies 
available in full text, involving more than 20 patients with 
non-metastatic muscle invasive bladder cancer (MIBC) stage 
T2-4a N0 M0, treated with RC or TMT, reporting 5-year 
overall survival (OS) rates were selected. 
Results: The median 5-year OS rate resulted to be 57% in TMT 
group, as compared with 52% (p=0.04), 51% (p=0.02) and 53% 
(p=0-38) in the whole group receiving RC or the group treated 
with RC alone or RC+chemotherapy, respectively. 
Multivariate analysis confirmed TMT as a significant 
prognostic variable. 
Conclusions: Compared with RC, TMT seems to be associated 
with better outcomes for patients with MIBC. The addition of 
chemotherapy may improve the RC outcome in some 
subgroup of patients with higher probability of 
micrometastases. Prospective randomized trials are 
warranted to verify these findings and better define the role 
of the organ-sparing and radical treatment strategy in the 
management of patients with MIBC. 
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Purpose/Objective: Adjuvant hormone therapy (HT) 
combined with radiotherapy (RT) improves prognosis in 
patients with intermediate-high risk prostate cancer (PC). 
However, HT produces several and debilitating side effects. 
There is no clear evidence in literature on the impact of 
integrated RT-HT treatment on QoL and particularly on 
fatigue. Therefore, aim of this study was to analyse the 
impact on QoL of type and duration of HT in patients 
undergoing RT for PC. 
Materials and Methods: Data from 5 clinical studies on RT in 
patients with PC were collected. The QoL was assessed 
before treatment and then after 2 and 5 years from RT 
according to the CLAS scale (CLAS1: quality of life; CLAS2: 
energy level; CLAS3: ability to perform daily activities). 
Average values of these parameters were calculated and 
compared based on HT (administered or not), type of HT 
(analogue vs anti-androgen), and HT duration (< 18 months vs 
≥ 18 months). 
Results: Data from 251 patients with 2 years follow-up and 91 
patients with 5 years follow-up were evaluated. Statistical 
analysis results are shown in the table below. 
 
Conclusions: Based on assessment of QoL in patients 
undergoing adjuvant RT +/- HT for PC, a significant reduction 
of the ability to perform daily activities was observed in 
patients treated with hormone therapy 2 years after RT. The 
lack of significant differences between CLAS values 5 years 
